Latest Pharmaceuticals News

Page 3 of 89
Vertex has raised its full-year 2026 revenue guidance after third-quarter sales climbed 12%, but the Crinetics acquisition sharply increased costs and debt. The next major test arrives on 30 November, when US regulators are due to rule on povetacicept for IgA nephropathy.
Ada Torres
Ada Torres
3 Nov 2026
The FDA has granted orphan drug designation to Neuren’s NNZ-2591 for neonatal hypoxic-ischemic encephalopathy, giving the programme potential US exclusivity and regulatory fee relief. The company is completing a juvenile animal safety study before targeting an IND submission in the first half of 2027.
Victor Sage
Victor Sage
2 Nov 2026
Adherium delivered a fifth consecutive quarterly record for remote patient monitoring revenue, but ended September with only A$120,000 in cash after a A$3.499 million operating outflow. Post-quarter loans and an AstraZeneca milestone payment have improved near-term liquidity, although further funding remains central to the company’s plans.
Victor Sage
Victor Sage
30 Oct 2026
CONNEQT Health ended the September quarter with just A$501,000 in cash after a A$3.06 million operating outflow, equivalent to 0.16 quarters of funding at the reported burn rate. The company is pursuing R&D-backed debt, inventory finance and an equity raising as Pulse sales recover from an inventory disruption.
Victor Sage
Victor Sage
30 Oct 2026
Xenitra has returned to positive quarterly gross profit as its new pharmaceutical and Web3 businesses begin generating revenue, but statutory operating cash flow remained negative at A$790,000. The company is now relying on procurement targets, repeat Web3 sales and further capital discipline to turn early commercial activity into sustainable cash generation.
Victor Sage
Victor Sage
30 Oct 2026
Zelira Therapeutics has only A$47,000 in cash after a quarterly operating outflow of A$56,000, while the proposed US$32.98 million HOPE 1 fundraising remains unclosed. The company says the funds are needed for an FDA application and Phase 1 trial, as its ASX quotation suspension continues.
Victor Sage
Victor Sage
30 Oct 2026
Recce Pharmaceuticals has cleared an active-comparator design for its pivotal Australian diabetic foot infection trial while an independent review of Indonesian Phase 3 data approaches. The biotech ended the quarter with A$1.04 million in cash, alongside expected tax rebates and unused financing facilities.
Victor Sage
Victor Sage
30 Oct 2026
Alterity Therapeutics says it has begun operational preparations for a Phase 3 ATH434 trial after FDA minutes confirmed the proposed design and registrational pathway in Multiple System Atrophy. The company ended September with A$41.3 million in cash, while a new US patent extends protection for ATH434 to 2045.
Ada Torres
Ada Torres
30 Oct 2026
Epsilon Healthcare delivered record September-quarter customer receipts of A$3.9 million, while nine-month revenue reached A$11.5 million. The growth story is strengthening, but cash fell to A$997,000 and quarterly operating cash flow remained negative.
Ada Torres
Ada Torres
30 Oct 2026
Paradigm Biopharmaceuticals’ pivotal knee osteoarthritis trial fell below its pre-specified continuation threshold, leaving the ASX-listed biotech in voluntary administration with A$4.33 million in cash. Administrators now have up to three months to assess restructuring options, clinical data and the company’s future.
Victor Sage
Victor Sage
30 Oct 2026
Epiminder has enrolled its 100th patient in the DETECT US epilepsy study ahead of schedule, while maintaining A$65.1 million in cash and no borrowings. The company says those reserves can fund clinical development and commercialisation work well into 2028.
Victor Sage
Victor Sage
30 Oct 2026
Algorae Pharmaceuticals has moved closer to its first expected NSW Health supply orders while reporting stronger preclinical results from its AOS2 drug-discovery platform. The company ended September with $3.15 million in cash and a further $3 million undrawn facility, but its commercial contract carries no minimum volume commitment.
Victor Sage
Victor Sage
30 Oct 2026

Browse the archive

Full archive